According to filings with the U.S. Securities and Exchange Commission, Marea Therapeutics is raising up to $160,418,629.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Josh Lehrer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardiometabolic diseases. The companys lead program, MAR001, is in Phase 2 clinical development and has the potential to become a new treatment for patients who remain at high risk of severe cardiovascular disease due to elevated remnant cholesterol and metabolic dysfunction. Marea is led by a dynamic team of scientists and company builders with deep know-how and experience in cardiometabolic diseases, human genetics and adipocyte biology.

To learn more about Marea Therapeutics, visit http://www.mareatx.com/
Company Linkedin Page: https://www.linkedin.com/company/marea-therapeutics/

Contact:
Josh Lehrer, Chief Executive Officer
617-501-9046
https://www.linkedin.com/in/josh-lehrer-8b33199/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.